Skip to main content
ROSSARI BIOTECH LIMITED logo

ROSSARI BIOTECH LIMITED — Investor Relations & Filings

Ticker · ROSSARI ISIN · INE02A801020 LEI · 335800R7XFRR8ZTHBQ25 BSE.NS Manufacturing
Open in API
Filings indexed 529 across all filing types
Latest filing 2023-10-30 Regulatory Filings
Country IN India
Listing BSE.NS ROSSARI

About ROSSARI BIOTECH LIMITED

https://www.rossari.com/

Rossari Biotech Limited is a specialty chemicals manufacturer focused on providing sustainable and innovative solutions across diverse sectors. The company operates through three primary business segments: Home, Personal Care and Performance Chemicals (HPPC), Textile Specialty Chemicals, and Animal Health and Nutrition. In the HPPC segment, it supplies essential ingredients for detergents, soaps, paints, and water treatment applications. Its textile division offers a comprehensive range of chemicals for the entire textile value chain, including pre-treatment, dyeing, and finishing processes. Additionally, the company provides high-quality feed additives and supplements for the poultry and livestock industries. Driven by robust research and development capabilities, Rossari Biotech emphasizes eco-friendly chemistry and customized formulations to meet specific client requirements. With advanced manufacturing facilities, the company serves a global clientele, maintaining a strong focus on operational excellence.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges informing them about scheduled investor and analyst meetings or conferences. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of events and information. The content explicitly states that the discussion will be based on previously submitted earnings presentations and publicly available information, and no unpublished price sensitive information will be shared. The document is short (1792 characters) and serves as an announcement of upcoming investor events rather than containing any financial data or detailed presentations itself. Therefore, it is best classified as an Investor Presentation announcement or notification. However, since it is not the presentation itself but an intimation of scheduled meetings, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and disclosures that do not fit other categories.
2023-10-30 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a full transcript of an earnings conference call for Rossari Biotech Limited covering Q2 and H1 FY24 results. It includes detailed management commentary on financial performance, operational highlights, strategic initiatives, and a Q&A session with analysts. The presence of detailed financial figures, discussion of revenue, EBITDA, PAT, segment performance, capacity expansions, and forward-looking statements are typical of earnings call transcripts. The document is not a brief announcement or a presentation but a full textual transcript of the call. Therefore, it fits the category of a Call Transcript (CT).
2023-10-27 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short communication notifying the availability of the audio recording of an earnings conference call for Q2 FY24. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) and provides a link to the recording on the company's website. The document does not contain the transcript itself, financial data, or detailed analysis, but merely informs about the recording's availability. Given the short length (1337 characters) and the nature of the content, this is an announcement related to a call transcript rather than the transcript itself. According to the rules, announcements about reports or recordings are classified as Regulatory Filings (RNS) because they do not contain the full transcript or substantive financial data.
2023-10-23 English
Copy of Newspaper Publication
Regulatory Filings Classification · 90% confidence The document text is mostly unreadable or corrupted, containing mostly non-standard characters and placeholders for omitted pictures. There is no clear indication of the document type, no recognizable keywords, regulatory references, fiscal period dates, or form names. The document length is 15,000 characters, which is substantial, but the content does not provide any meaningful information to classify it as a specific report type. Given the lack of identifiable content and the fallback rule, the document should be classified as a Regulatory Filing (RNS), which is the default category for filings that do not fit other categories.
2023-10-23 English
Investor Presentation
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Q2 FY24 Earnings Presentation' and dated October 22, 2023. It contains detailed financial data including revenue, EBITDA, PAT, segment-wise revenue, consolidated balance sheet, cash flows, and management commentary on quarterly performance. The content is comprehensive and focused on quarterly financial results and operational discussions. It is not a brief announcement or a certification letter, nor is it a full annual report. The presence of detailed financial statements and analysis for a quarter indicates it is an Interim / Quarterly Report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q2 2024
2023-10-22 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated October 22, 2023, announcing the financial results for the quarter ended September 30, 2023 (Q2 FY24). It contains detailed financial performance data including revenue, EBITDA, PAT, and EPS for the quarter and half-year periods, along with management commentary and key developments such as capacity expansion plans. The document is not a full annual or interim report but an initial announcement of quarterly financial results with key highlights. It is not a transcript, audit report, or regulatory filing. Therefore, it fits the definition of an Earnings Release (ER). The document length (9076 characters) supports it being a full press release rather than a brief announcement or certification. Hence, the classification is ER with high confidence. Q2 2024
2023-10-22 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.